Revisor Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$854K Sell
712
-87
-11% -$88.9K 0.21% 127
2026
Q1
$735K Sell
799
-60
-7% -$60.8K 0.2% 124
2025
Q4
$932K Buy
859
+94
+12% +$89.9K 0.25% 100
2025
Q3
$654K Buy
765
+51
+7% +$38K 0.23% 97
2025
Q2
$565K Buy
714
+72
+11% +$55.9K 0.2% 114
2025
Q1
$530K Sell
642
-65
-9% -$54.1K 0.24% 91
2024
Q4
$551K Sell
707
-478
-40% -$396K 0.51% 40
2024
Q3
$1.05M Buy
1,185
+36
+3% +$32.4K 0.66% 29
2024
Q2
$1.04M Sell
1,149
-793
-41% -$634K 0.72% 26
2024
Q1
$1.32M Buy
+1,942
New +$1.38M 0.6% 32

Other funds holding LLY

Revisor Wealth Management's LLY Position: Q2 2026 in Review

Revisor Wealth Management reduced its Eli Lilly (LLY) stake by 11% in Q2 2026, selling an estimated $88.9K and leaving 712 shares worth $854K. The position accounts for 0.21% of the portfolio, ranked #127.

Revisor Wealth Management first reported a position in LLY in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.32M in Q1 2024. 1,691 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Revisor Wealth Management held 712 shares of Eli Lilly worth $854K as of Q2 2026.
  • Revisor Wealth Management sold 87 Eli Lilly shares in Q2 2026, an estimated $88.9K.
  • Eli Lilly made up 0.21% of Revisor Wealth Management's portfolio in Q2 2026, its #127 holding.
  • Revisor Wealth Management first reported a position in Eli Lilly in Q1 2024 and has held it in 10 quarters since.
  • Revisor Wealth Management's Eli Lilly position peaked at $1.32M in Q1 2024.
  • 1,691 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Revisor Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.